Register now to learn about a new option for relapsed or refractory follicular lymphoma

Immunotherapy in the Age of COVID-19

BRIELLE BENYON
Saturday, August 15, 2020


Immunotherapy has become a mainstay in the treatment of non-small cell lung cancer, but more recently, it has moved into the small cell lung cancer space, too. In this episode of “The Vitals,” Beth Sandy, NP, a nurse practitioner at the University of Pennsylvania Abramson Cancer Center, discusses the immune-related adverse events (irAEs) that nurses need to be aware of when treating patients with these agents.

Sandy also discussed how some irAEs, such as difficulty breathing – which is more common in lung cancer than other tumor types – can be similar to coronavirus disease 2019 (COVID-19) symptoms. She offered advice on how to determine which it is in this unprecedented time in oncology nursing.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.